

Bayer Key Data, Second Quarter and First Half of 2018

(Some prior-year figures restated)

Bayer Group (EUR million)	Q2 2017	Q2 2018	Change %	H1 2017	H1 2018	Change %
Sales	8,714	9,481	+8.8	18,394	18,619	+1.2
EBITDA before special items	2,247	2,335	+3.9	5,301	5,231	-1.3
EBIT	1,463	1,351	-7.7	3,890	3,661	-5.9
<i>Special items</i>	-244	-363	-	-346	-441	-
EBIT before special items	1,707	1,714	+0.4	4,236	4,102	-3.2
Net income	1,224	799	-34.7	3,307	2,753	-16.8
Earnings per share (EUR)	1.38	0.87	-37.0	3.74	3.06	-18.2
Core earnings per share (EUR)	1.52	1.54	+1.3	3.80	3.77	-0.8
Number of employees*	99,720	124,055	+24.4	99,720	124,055	+24.4

Pharmaceuticals (EUR million)	Q2 2017	Q2 2018	Change %	H1 2017	H1 2018	Change %
Sales	4,304	4,217	-2.0	8,567	8,292	-3.2
EBITDA before special items	1,481	1,363	-8.0	2,983	2,778	-6.9
EBIT	1,102	1,053	-4.4	2,321	2,216	-4.5
<i>Special items</i>	-120	-56	-	-156	-57	-
EBIT before special items	1,222	1,109	-9.2	2,477	2,273	-8.2

Consumer Health (EUR million)	Q2 2017	Q2 2018	Change %	H1 2017	H1 2018	Change %
Sales	1,542	1,413	-8.4	3,143	2,822	-10.2
EBITDA before special items	314	256	-18.5	706	569	-19.4
EBIT	195	157	-19.5	473	368	-22.2
<i>Special items</i>	-15	1	-	-24	-4	-
EBIT before special items	210	156	-25.7	497	372	-25.2

Crop Science (EUR million)	Q2 2017	Q2 2018	Change %	H1 2017	H1 2018	Change %
Sales	2,163	3,011	+39.2	5,283	5,872	+11.1
EBITDA before special items	317	631	+99.1	1,432	1,673	+16.8
EBIT	117	154	+31.6	1,087	1,046	-3.8
<i>Special items</i>	-95	-280	-	-132	-341	-
EBIT before special items	212	434	+104.7	1,219	1,387	+13.8

Animal Health (EUR million)	Q2 2017	Q2 2018	Change %	H1 2017	H1 2018	Change %
Sales	450	453	+0.7	890	867	-2.6
EBITDA before special items	116	128	+10.3	251	267	+6.4
EBIT	107	116	+8.4	233	245	+5.2
<i>Special items</i>	0	-3	-	0	-3	-
EBIT before special items	107	119	+11.2	233	248	+6.4

EBIT(DA) before special items and core earnings per share are not defined in the International Financial Reporting Standards and should therefore be regarded only as supplementary information. For the definition of these indicators, see the current annual report at www.bayer.com.

* Full-time equivalents at end of period